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OCCURRENCE OF CO-COLONIZATION OR
CO-INFECTION WITH VANCOMYCIN-RESISTANT
ENTEROCOCCI AND METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS IN A MEDICAL INTENSIVE
CARE UNIT
David K. Warren, MD; Anand Nitin, MD; Cheri Hill, BS; Victoria J. Fraser, MD; Marin H. Kollef, MD

ABSTRACT
OBJECTIVE: To determine the occurrence of co-colonization or co-infection with VRE and MRSA among medical
patients requiring intensive care.
DESIGN: Prospective, single-center, observational study.
SETTING: A 19-bed medical ICU in an urban teaching
hospital.
PATIENTS: Adult patients requiring at least 48 hours of
intensive care and having at least one culture performed for
microbiologic evaluation.
RESULTS: Eight hundred seventy-eight consecutive
patients were evaluated. Of these patients, 402 (45.8%) did not
have microbiologic evidence of colonization or infection with
either VRE or MRSA, 355 (40.4%) were colonized or infected with
VRE, 38 (4.3%) were colonized or infected with MRSA, and 83
(9.5%) had co-colonization or co-infection with VRE and MRSA.
Multiple logistic regression analysis demonstrated that increas-

Until the development of the oxazolidinones and
quinupristin/dalfopristin, vancomycin had been the only
uniformly effective antibiotic for the treatment of
Staphylococcus aureus infections in the United States. In
1997, the first incidence of S. aureus with reduced susceptibility to vancomycin was described.1 This was followed by at least eight reports of similar S. aureus strains
in the United States.2-6 Recently, two infections due to vancomycin-resistant S. aureus have been described.7,8 Both
of these isolates contained the vanA gene, and in one of
the isolates, it was identical to the vanA gene present in
Enterococcus faecalis cultured from the same patient.7
These two reports suggest that the vanA gene was
acquired by S. aureus from vancomycin-resistant enterococci (VRE) in these two patients having prior co-colonization with methicillin-resistant S. aureus (MRSA) and
VRE.
The occurrence of colonization with VRE and
MRSA appears to be common among patients requiring
intensive care.9,10 MRSA has become the predominant
form of clinically significant S. aureus within intensive

ing age, hospitalization during the preceding 6 months, and
admission to a long-term–care facility were independently associated with colonization or infection due to VRE and co-colonization or co-infection with VRE and MRSA. The distributions of positive culture sites for VRE (stool, 86.7%; blood, 6.5%; urine, 4.8%;
soft tissue or wound, 2.0%) and for MRSA (respiratory secretions,
34.1%; blood, 32.6%; urine, 17.1%; soft tissue or wound, 16.2%)
were statistically different (P < .001).
CONCLUSIONS: Co-colonization or co-infection with
VRE and MRSA is common among medical patients requiring
intensive care. The recent emergence of vancomycin-resistant
Staphylococcus aureus and the presence of a patient population cocolonized or co-infected with VRE and MRSA support the need
for aggressive infection control measures in the ICU (Infect
Control Hosp Epidemiol 2004;25:99-104).

care units (ICUs) and increasingly within some community settings as well.9,11-15 However, there are few data indicating the frequency with which concomitant colonization
or co-infection with MRSA and VRE occurs within the
same patient. Given the important clinical implications of
S. aureus developing vancomycin resistance, we performed a clinical study in which the main goal was to
determine the occurrence of concomitant colonization or
co-infection with VRE and MRSA among patients admitted
to an ICU.
METHODS

Study Location and Patients
This study was conducted at Barnes–Jewish
Hospital, a university-affiliated, urban teaching hospital
with 1,400 beds. During the 28-month period from
February 2000 to October 2001, all patients requiring
admission to the 19-bed medical ICU for more than 48
hours were eligible for this investigation. These inclusion
criteria were prospectively selected to minimize the
enrollment of patients with rapidly fatal illnesses and self-
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limited conditions not requiring more prolonged intensive
care. The medical ICU is a closed unit with a multidisciplinary team providing patient care under the direction of
attending physicians who are board certified in critical
care medicine. This study was approved by the
Washington University School of Medicine Human
Studies Committee.
Study Design and Data Collection
A prospective cohort study design was employed,
with the main outcome measure being concomitant colonization or co-infection with VRE and MRSA. We also
assessed secondary outcomes including the lengths of
hospitalization and intensive care, the number of acquired
organ system derangements, and hospital mortality.
For all patients included in the study, the following
characteristics were prospectively recorded by one of the
investigators: age; gender; ethnicity; severity of illness
based on Acute Physiology and Chronic Health Evaluation
II (APACHE II) scores16; the presence of congestive heart
failure, chronic obstructive pulmonary disease, underlying
malignancy, recent chemotherapy, seropositivity for human
immunodeficiency virus, diabetes mellitus, chronic renal
insufficiency, cirrhosis, and solid organ transplantation;
and the administration of corticosteroids.
One of the investigators made daily rounds in the
medical ICU to identify eligible patients. Patients included
in the study were prospectively observed until they were
discharged from the hospital or died. Discharge from the
hospital was defined as transfer of a patient from the hospital to his or her home, a skilled nursing facility, or a private rehabilitative hospital. All culture results and clinical
data were prospectively and independently reviewed by a
board-certified infectious disease physician (VJF).
Patients could not be entered into the study more than
once during the same hospitalization.
Definitions
All definitions were selected prospectively as part of
the original study design. We calculated APACHE II scores
on the basis of the clinical data available from the first 24hour period of intensive care.16 The criteria for acquired
organ system derangements were those used by Rubin et
al.17 One point was given for acquired dysfunction of each
organ system. Renal dysfunction was defined as a twofold
increase in baseline creatinine level or an absolute increase
in baseline creatinine level of 2.0 mg/dL. Hepatic dysfunction was defined as an increase in total bilirubin level to
more than 2.0 mg/dL. Pulmonary dysfunction was defined
as one of the following: (1) a requirement for mechanical
ventilation for a diagnosis of pneumonia, chronic obstructive pulmonary disease, asthma, or pulmonary edema (cardiogenic or noncardiogenic); (2) a PaO2 level of less than
60 mm Hg while receiving a fraction of inspired oxygen of
0.50 or more; or (3) the use of at least 10 cm of H2O of positive end-expiratory pressure. Neurologic dysfunction was
defined as a new focal deficit (eg, hemiparesis after cerebral infarction) or a new generalized process (eg, seizures
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or coma). Gastrointestinal dysfunction was defined as gastrointestinal hemorrhage requiring transfusion, new ileus,
or diarrhea lasting more than 24 hours and unrelated to
previous bowel surgery. Cardiac dysfunction was defined
as acute myocardial infarction, cardiac arrest, or the new
onset of congestive heart failure.
Infection Control and Surveillance Protocol
Healthcare workers and visitors were required to
wear both gloves and gowns before entry into rooms of
patients on contact isolation or contact precautions.
Contact precautions were used for patients colonized or
infected with VRE, MRSA, multidrug-resistant gram-negative bacilli, or Clostridium difficile. Additionally, a commercially available alcohol-based disinfectant foam
(Alcare Plus, Steris Corporation, St. Louis, MO) or good
handwashing were required for hand disinfection prior to
all patient contacts. The alcohol-based foam was dispensed from canisters placed at the entrance of every
patient room. These specific infection control practices
had previously been shown to reduce the acquisition of
VRE in this medical ICU.18
In conjunction with the contact precautions described,
the medical ICU employs specific protocols to reduce the
occurrence of hospital-acquired infections. Protocols directed at weaning patients from mechanical ventilation,19 reducing unnecessary sedation,20 and providing appropriate enteral nutritional support21 are in place and have been associated
with reductions in hospital-acquired infections. Additionally,
two education-based programs to reduce the occurrence of
ventilator-associated pneumonia and catheter-related bloodstream infection, respectively, were employed in this ICU.22,23
As part of the ICU surveillance program, nurses
obtained samples for stool cultures or rectal swab cultures
for VRE from the patients on admission, weekly, and at the
time of discharge from the ICU.24 Bile esculin azide agar
with vancomycin (6 µg/mL; Remel, Lenexa, KS), followed
by a subculture on a 30-µg vancomycin disk, was used for
isolation, identification, and characterization of enteric
VRE, as described elsewhere.25 Because vanA and vanB
fail to produce inhibition zones of greater than 6 mm,
whereas vanC isolates primarily produce inhibition zones
of greater than 15 mm during subculturing on a 30-µg vancomycin disk, this method reliably differentiates clinically
and epidemiologically relevant species.25 In addition, all
stool samples submitted for C. difficile testing were routinely tested for enteric VRE.25,26
A patient was considered to have enteric colonization with VRE if a clinical culture or surveillance culture
of a rectal swab or stool sample was positive for VRE.
Colonization or infection with MRSA was defined as a positive clinical culture. Surveillance cultures from the nares
or other locations for MRSA were not routinely performed
during this investigation.
Statistical Analysis
All comparisons were unpaired and all tests of significance were two-tailed. Continuous variables were com-
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pared using the Student’s t test for normally distributed
variables and the Wilcoxon rank sum test for non-normally distributed variables. The chi-square or Fisher’s exact
test was used to compare categorical variables. The primary data analysis compared patients according to the
presence or absence of colonization or infection with VRE
and MRSA (alone or in combination). We performed multiple logistic regression analysis using a commercial statistical package (SPSS software, version 10.0 for
Windows; SPSS, Inc., Chicago, IL).
A stepwise approach was used to enter new terms
into the logistic regression model. Colonization or infection with VRE, colonization or infection with MRSA, and
co-colonization or co-infection with VRE and MRSA were
the three dependent outcome variables examined, and .05
was set as the limit for the acceptance or removal of new
terms. Variables with a P value of less than .15 were
entered into the multivariate analysis based on models
that were judged a priori to be clinically sound.27 This was
prospectively determined to be necessary to avoid producing spuriously significant results with multiple comparisons. Results of the logistic regression analyses are
reported as adjusted odds ratios (ORs) with 95% confidence intervals (CI95). Values are expressed as the mean
± standard deviation (continuous variables) or as a percentage of the group from which they were derived (categorical variables). All P values were two-tailed, and P values of .05 or less were considered to indicate statistical
significance.
RESULTS

Patients
A total of 878 consecutive patients requiring admission to the medical ICU for more than 48 hours were evaluated. The mean age of the patients was 59.0 ± 17.0 years
(range, 15 to 102 years) and the mean APACHE II score
was 23.2 ± 7.4 (range, 5 to 47). There were 431 (49.1%)
male and 447 (50.9%) female patients.
Co-Colonization or Co-Infection With VRE and
MRSA
Four hundred two (45.8%) of the patients had no
microbiologic evidence of colonization or infection with
VRE or MRSA during their stay in the ICU. Three hundred fifty-five (40.4%) of the patients had colonization or
infection with VRE, 38 (4.3%) of the patients had colonization or infection with MRSA, and 83 (9.5%) of the
patients had co-colonization or co-infection with VRE and
MRSA. The distribution of the sites of infection is given
in Table 1. VRE was cultured statistically more often
from stool samples or rectal swabs compared with MRSA
(86.7% vs 0.0%; P < .001). MRSA was isolated more often
from respirator y secretions (34.1% vs 0.0%; P < .001) and
from blood (32.6% vs 6.5%; P < .001). Among all of the cultures evaluated, 7 blood cultures were positive for VRE
and MRSA in the same patient. Two wound cultures
from the same patients were also positive for VRE and
MRSA.

AND

MRSA

101

TABLE 1
SITES OF INFECTION
Site

VRE
(n = 504)

MRSA
(n = 139)

Blood
Respiratory secretions
Urine
Soft tissue or wound
Rectum or stool

33 (6.5%)
0 (0.0%)
24 (4.8%)
10 (2.0%)
437 (86.7%)

42 (32.6%)
44 (34.1%)
22 (17.1%)
21 (16.2%)
0 (0.0%)*

VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus.
*MRSA was not actively screened for in the rectal or stool cultures due to the presence of vancomycin-impregnated culture media.

Risk Factors for Colonization or Infection With
VRE and MRSA
Compared with patients who did not have colonization or infection, patients with colonization or infection
due to VRE were statistically older and more likely to have
chronic obstructive pulmonary disease, chronic renal failure, outpatient hemodialysis, hospitalization during the 6
months preceding the current hospitalization, and admission to the ICU from a long-term–care facility (Table 2).
Similarly, patients with colonization or infection due to
MRSA were statistically older and more likely to have
chronic obstructive pulmonary disease, prior hospitalization, and admission to the ICU from another hospital compared with patients who did not have colonization or infection. Patients with colonization or infection due to MRSA
were statistically more likely to have underlying malignancy and admission to the ICU from another hospital and
statistically less likely to have chronic renal failure compared with patients colonized or infected with VRE.
Patients co-colonized or co-infected with VRE and MRSA
were statistically older and more likely to have chronic
obstructive pulmonary disease, prior hospitalization, and
admission to the ICU from a long-term–care facility compared with patients who did not have colonization or infection with these microorganisms. Patients with
co-colonization or co-infection with VRE and MRSA were
statistically less likely to have chronic renal failure and
outpatient dialysis compared with patients with colonization or infection due to VRE.
Multiple logistic regression analysis showed that
increasing age (adjusted OR, 1.02; CI95, 1.01 to 1.03), hospitalization during the 6 months preceding the current
hospitalization (adjusted OR, 2.74; CI95, 2.21 to 3.40), and
admission from a long-term–care facility (adjusted OR,
1.30; CI95, 1.14 to 1.47) were independently associated
with colonization or infection due to VRE. The same
three variables with similar adjusted ORs were independently associated with co-colonization or co-infection with
VRE and MRSA. Prior hospitalization was the only variable independently associated with colonization or infection due to MRSA (adjusted OR, 7.35; CI95, 3.96 to
13.67).
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PATIENT CHARACTERISTICS ACCORDING

Characteristic
Mean age, y (± SD)
Gender
Male
Female
Ethnicity
White
Black
Other
Mean APACHE II score (± SD)
Surgery
Congestive heart failure
COPD
Underlying malignancy
Chemotherapy
HIV positive
Diabetes mellitus
Received corticosteroids
Chronic renal failure
Outpatient hemodialysis
Cirrhosis
Organ transplant
Prior hospitalization
Admission location
Other hospital
Hospital ward
Home
Long-term–care facility
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MICROORGANISM
Patients With
Neither
VRE or MRSA
(n = 402)

Patients With
VRE
Only
(n = 355)

Patients With
MRSA
Only
(n = 38)

Patients With
Both VRE
and MRSA
(n = 83)

56.3 (± 17.3)

60.4 (± 16.7)*

62.6 (± 17.4)*

63.9 (± 13.4)*

191 (47.5%)
211 (52.5%)

174 (49.0%)
181 (51.0%)

19 (50.0%)
19 (50.0%)

47 (56.6%)
36 (43.4%)

248 (61.7%)
151 (37.6%)
3 (0.7%)
23.8 (± 7.4)
30 (7.5%)
70 (17.4%)
93 (23.1%)
48 (11.9%)
10 (2.5%)
14 (3.5%)
120 (29.9%)
146 (36.3%)
99 (24.6%)
33 (8.2%)
38 (9.5%)
21 (5.2%)
138 (34.3%)

197 (55.5%)
153 (43.1%)
5 (1.4%)
24.7 (± 6.7)
20 (5.6%)
69 (19.4%)
111 (31.3%)*
29 (8.2%)
5 (1.4%)
16 (4.5%)
126 (35.5%)
142 (40.0%)
117 (33.0%)*
56 (15.8%)*
22 (6.2%)
29 (8.2%)
205 (57.7%)*

27 (71.1%)
11 (28.9%)
0 (0.0%)
24.2 (± 6.2)
1 (2.6%)
7 (18.4%)
15 (39.5%)*
8 (21.1%)†
2 (5.3%)
0 (0.0%)
14 (36.8%)
10 (26.3%)
6 (15.8%)†
3 (7.9%)
2 (5.3%)
2 (5.3%)
22 (57.9%)*

54 (65.1%)
26 (31.3%)
3 (3.6%)
25.4 (± 7.7)
9 (10.8%)
16 (19.3%)
31 (37.3%)*
8 (9.6%)
0 (0.0%)
0 (0.0%)
39 (47.0%)
32 (38.6%)
17 (20.5%)†
5 (6.0%)†
6 (7.2%)
5 (6.0%)
41 (49.4%)*

105 (26.1%)
161 (40.0%)
126 (31.3%)
10 (2.5%)

63 (17.7%)*
184 (51.8%)
73 (20.6%)
35 (9.9%)

16 (42.1%)*,†
7 (18.4%)
13 (34.2%)
2 (5.3%)

19 (22.9%)*,‡
33 (39.8%)
19 (22.9%)
12 (14.5%)

VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus; SD = standard deviation; APACHE = Acute Physiology and Chronic Health Evaluation; COPD = chronic
obstructive pulmonary disease; HIV = human immunodeficiency virus.
*P < .05 for comparison with the group who had neither organism cultured.
†
P < .05 for comparison with the group who had VRE identified in culture.
‡
P < .05 for comparison with the group who had MRSA identified in culture.

Secondary Outcomes
Patients with colonization or infection due to VRE
had statistically longer hospital stays compared with uninfected patients (Table 3). Patients with co-colonization or
co-infection with VRE and MRSA had statistically longer
stays in the hospital and in the ICU, longer duration of
mechanical ventilation, and a greater likelihood of hospital discharge to a long-term–care facility compared with
patients who did not have colonization or infection with
VRE and MRSA.
DISCUSSION

We demonstrated that co-colonization or co-infection with VRE and MRSA was common among patients
admitted to a medical ICU, occurring in 9.5%. Increasing
patient age, hospitalization during the preceding 6

months, and admission to the ICU from a long-term–care
facility were identified as independent risk factors for cocolonization or co-infection with VRE and MRSA. Co-colonized or co-infected patients also had statistically longer
stays in the hospital and ICU and were statistically more
likely to require admission to a long-term–care facility following hospital discharge compared with patients who did
not have VRE and MRSA colonization or infection.
Despite the widespread presence of patients colonized or infected with VRE and MRSA in ICUs, no previous study has examined the occurrence of co-colonization
or co-infection with these gram-positive bacteria within
the same patient in this clinical setting. Previous investigations among hospitalized patients and patients in
skilled-care facilities suggest that those colonized with
VRE are at increased risk for colonization or infection
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TABLE 3
CLINICAL OUTCOMES

Outcome
Variable
Mean no. of acquired organ system
derangements (± SD)
Mean hospital stay, d (± SD)
Mean ICU stay, d (± SD)
Mean duration of mechanical ventilation, d (± SD)
Disposition of hospital survivors
Home
Long-term–care facility
Outside hospital

Patients With
Neither
VRE or MRSA
(n = 402)

Patients With
VRE
Only
(n = 355)

Patients With
MRSA
Only
(n = 38)

Patients With
Both VRE
and MRSA
(n = 83)

1.8 (± 1.1)

1.8 (± 1.0)

1.6 (± 1.0)

1.7 (± 1.0)

22.1 (± 22.8)
9.1 (± 8.0)
10.6 (± 12.0)

28.3 (± 29.4)*
9.8 (± 8.6)
12.3 (± 14.3)

27.8 (± 27.2)
10.1 (± 7.4)
10.6 (± 8.1)

29.4 (± 24.2)*
13.3 (± 10.3)*,†
17.8 (± 20.8)*,†

15 (55.6%)
11 (40.7%)
1 (3.7%)

22 (40.0%)*
31 (56.4%)*
2 (3.6%)

182 (60.7%)
102 (34.0%)
16 (5.3%)

119 (52.9%)
96 (42.7%)
10 (4.4%)

VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus; SD = standard deviation; ICU = intensive care unit.
*Comparison with the group who had neither organism cultured.
†
Comparison with the group who had VRE identified in culture.

with MRSA and S. aureus displaying intermediate resistance to vancomycin.28-30 The clinical importance of co-colonization or co-infection with these pathogens is highlighted by the recent description of vancomycin-resistant
S. aureus occurring as a result of the transfer of the vanA
gene from VRE.7,8 Although the acquired vancomycinresistant genes vanA, vanB, vanD, vanE, vanF, and vanG
have been reported in VRE, transfer of the vanA gene to
S. aureus appears to be a rare event.7 This suggests that
the transfer requires specific conditions as suggested by
the difficulty encountered attempting in vitro conjugate
transfer of the vanA gene from enterococci to S. aureus.31
Although recommended measures to control the
spread of VRE and MRSA in hospitals have been promoted for several years, surveillance data suggest that the
existence of these recommendations has not appreciably
slowed the increasing rate of infection or colonization
with either of these organisms in the United States.32,33
The reasons for this lack of effect are unclear and under
debate. In some institutions, the recommended measures
may be ineffective or poorly followed or implemented.
However, increasing evidence suggests that well-targeted
inter vention programs implemented within motivated
healthcare environments can reduce the occurrence of
colonization as well as infection with these antibiotic-resistant, gram-positive bacteria.
Our study has several limitations. First, it was performed within a single ICU with relatively high rates of
colonization or infection with VRE, especially among
patients admitted from other healthcare settings.
Therefore, the results may not be generalizable to ICUs
and hospitals with different sources of patient referral.
However, the escalating rates of VRE and MRSA in the
United States suggest that co-colonization or co-infection
with these bacteria is likely to be a more widespread

occurrence. Second, we did not differentiate colonization
from infection in this study. This was purposefully done
because our intent was to identify the coexistence of VRE
and MRSA among the same patients. Third, we did not
specifically examine the use of antibiotics as a risk factor
for the acquisition of VRE and MRSA as has been previously reported.32 However, recent investigations have
found that patients with healthcare-acquired sources of
infection have bacterial pathogens associated with infection that are similar to those seen in hospital-acquired
infection, and that antibiotic exposure is common among
these patients.34
Another important potential limitation of our study
is that we examined only clinical cultures for MRSA, and
although we performed active surveillance of VRE, we
used a selective medium for stool cultures containing vancomycin to select out for VRE. Therefore, we likely
underestimated the occurrence of colonization and infection with MRSA in this population. This underreporting
bias also limits the accuracy of the risk factors for infection and colonization with MRSA identified in this analysis. Other investigators have estimated that approximately 55% of patients colonized with MRSA are detected by
clinical cultures alone compared with clinical cultures
combined with active surveillance.35,36 With the use of this
approximation, it is likely that the true incidence of co-colonization or co-infection with VRE and MRSA is closer to
15% or 20%. Finally, we did not differentiate between
patients colonized or infected with MRSA and VRE on
admission to the ICU and patients who acquired these
pathogens during their stay in the ICU. As a result, the
risk factors identified for colonization or infection with
these organisms may not be applicable to specific patient
subgroups (eg, patients acquiring VRE, MRSA, or both
while in the ICU).
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Despite these limitations, we demonstrated that coinfection with VRE and MRSA is common among critically ill patients. Clinicians should be aware of the potential
for co-infection with VRE and MRSA in the ICU setting.
Appropriate infection control practices should be in place
to limit the horizontal transmission of VRE and MRSA to
minimize the future potential for concomitant colonization
or co-infection and the transfer of resistance genes among
these pathogens.
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